U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   Form 10-QSB

      QUARTERLY REPORT  PURSUANT TO SECTION 13 OR 15(d) OF THE
      SECURITIES  EXCHANGE ACT OF 1934

      For the quarter ended March 31, 1999

      Commission file no. 0-24921

                         Surgical Safety Products, Inc.
                  --------------------------------------------
                 (Name of small business issuer in its charter)

          New York                                    65-0565144
-------------------------------                   -------------------
(State or other jurisdiction of                    (I.R.S. Employer
incorporation or organization)                     Identification No.)

         2018 Oak Terrace
        Sarasota, Florida                              34231
---------------------------------------             ----------
(Address of principal executive offices)            (Zip Code)

Issuer's telephone number (941) 927-7874

Securities registered under Section 12(b) of the Exchange Act:

                                                Name of each exchange on
      Title of each class                       which registered

            None
-----------------------------                   -------------------------

Securities registered under Section 12(g) of the Exchange Act:

                          Common Stock, $.001 par value
                       -----------------------------------
                                (Title of class)




<PAGE>



                        Copies of Communications Sent to:

                              Mercedes Travis, Esq.
                              Mintmire & Associates
                          265 Sunrise Avenue, Suite 204
                              Palm Beach, FL 33480
                               Tel: (561) 832-5696
                               Fax: (561) 659-5371



     Indicate by Check  whether the issuer (1) filed all reports  required to be
filed by Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or
for such shorter  period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

Yes  X      No
       ---        ---

     As of March  31,1999,  there are  10,736,973  shares of voting stock of the
registrant issued and outstanding.





<PAGE>



                                     PART I

Item 1.     Financial Statements






Condensed Balance Sheets for the Quarters Ended March 31, 1999 and 1998      F-2

Condensed Statements of Operations for the Three Months Ended March
      31, 1999 and 1998                                                      F-3

Statements of Cash Flows for the Three Months Ended March 31, 1999
      and 1998                                                               F-4

Footnotes to the Financial Statements                                        F-6





<PAGE>



<TABLE>
<CAPTION>

                       SURGICAL SAFETY PRODUCTS, INC.
                           CONDENSED BALANCE SHEET
<S>                                        <C>               <C>
Assets                                       (Unaudited)
Current Assets                             March 31, 1999    December 31, 1998
                                           -------------     -----------------
 Cash                                       $          0              $41,191
 Accounts receivable                              22,793                1,941
 Deposits                                              0               58,700
 Inventory                                         6,337                6,555
                                             -----------          -----------
Total current assets                              29,130              108,837
                                             -----------          -----------
Property and equipment, net                      176,995              112,772
                                             -----------          -----------
Other Assets
   Intangible assets, net                         47,821               49,232
  Software development costs, net                125,917               92,873
  Other assets                                    10,250               10,250
                                             -----------          -----------
    Total other assets                           183,988              152,355
                                             -----------          -----------
Total Assets                                    $390,113             $373,514
                                                 =======              =======
Liabilities and Stockholders' Equity
Current Liabilities
 Line of credit                                $ 100,000                    $
 Notes payable - related parties                  70,000
 Accounts payable and accrued expenses           100,899               55,331
                                           -------------          -----------
Total current liabilities                        270,899               55,331
                                           -------------          -----------
Stockholders' Equity
 common stock, $.001 par value,
  20,000,000 shares authorized;
 10,786,973 shares issued and
  outstanding in 1999 and 1998                    10,787               10,787
Additional paid-in capital                     1,907,129            1,998,242
Accumulated deficit                           (1,798,702)          (1,690,846)
                                        ----------------     ----------------
Total stockholders' equity                       119,214              318,183
                                        ----------------     ----------------
Total Liabilities and Stockholders' Equity     $ 390,113             $373,514
                                               =========             ========
</TABLE>

   The accompanying notes are an integral part of these financial statements.
                                       F-2



<PAGE>


<TABLE>
<CAPTION>

                       SURGICAL SAFETY PRODUCTS, INC.
                     CONDENSED STATEMENTS OF OPERATIONS
                 THREE MONTHS ENDED MARCH 31, 1999 AND 1998
                                 (UNAUDITED)
<S>                                          <C>                 <C>
                                                1999                  1998
                                                -----                 -----
Revenue                                        $  39,577            $  15,980

Costs and expenses
 Cost of medical products sold                       261                  153
 Operating expenses                              138,984               63,274
 Research and development expenses                 6,667                5,138
 Interest expense                                  1,521                1,343
                                             -----------          -----------
Total costs                                      147,433               69,908
                                             -----------          -----------
Net loss before income taxes                   (107,856)             (53,928)
Provision for income taxes                             0                    0
                                             -----------          -----------
Net loss                                     $ (107,856)           $ (53,928)
                                                ========              =======
Net loss per share                              $ (0.01)             $ (0.01)
                                                ========              =======
</TABLE>












   The accompanying notes are an integral part of these financial statements.
                                       F-3



<PAGE>


<TABLE>
<CAPTION>


                       SURGICAL SAFETY PRODUCTS, INC.
                           STATEMENT OF CASH FLOWS
                 THREE MONTHS ENDED MARCH 31, 1999 AND 1998
                                 (UNAUDITED)
                                              1999                  1998
                                              -----                 -----
<S>                                        <C>                   <C>
Cash Flows From Operating Activities
 Net loss                                $     (107,856)         $   (53,928)
                                          --------------          -----------
 Adjustments to reconcile net loss to cash
 used in operating activities
   Depreciation and amortization                 29,905                2,426
   Common stock issued for services                                   12,500
   Stock option compensation expense            (91,113)
 Decrease (increase) in operating assets
 Receivables                                    (20,852)             250,125
 Inventory                                          218               (3,087)
Increase (decrease) in operating liabilities
 Accounts payable and accrued expenses           45,570              (56,580)
                                             ----------            ----------
    Total adjustments                           (36,272)             250,384
                                             -----------           ----------
       Net cash used in operating activities   (144,128)             151,456
                                             -----------           ----------
Cash Flows From Investing Activities
 Furniture and equipment purchased              (25,937)              (8,568)
 Software development additions                 (41,126)              (9,888)
 Patent and trademark costs
                                             -----------            ---------
Net cash used in investing activities           (67,063)             (18,456)
                                             -----------            ---------
Cash Flows From Financing Activities
 Proceeds from related party loans               70,000
 Advances (repayments) on line of credit, net   100,000              (75,000)
 Repayment of stockholder loans                                      (58,000)
                                             ----------             ---------
 Net cash provided by financing activities      170,000             (133,000)
                                             -----------           ----------
Net increase (decrease) in cash                 (41,191)                   -
Cash at beginning of year                        41,191                    -
                                             -----------           ----------
Cash at end of year                          $         -            $      -
                                                ========              =======
Supplemental Cash Flow Information:            $   1,521            $ 19,010
 Cash paid for interest                         ========               ======
</TABLE>

   The accompanying notes are an integral part of these financial statements.
                                       F-4


<PAGE>



For the  purposes of the  statement  of cash  flows,  management  considers  all
deposits and financial  instruments with original  maturities of less than three
months to be cash and cash equivalents.



Material  non-cash  transactions  not  reflected in the  statement of cash flows
include:



For the Quarter Ended March 31, 1999
     The Company  received  fixed  assets in the amount of $ 58,700 for which it
had recorded deposits of such amount at December 31, 1998.



For the Quarter Ended March 31, 1998
     The Company  issued  common  stock for prepaid  legal and public  relations
services in the amount of $ 47,500 as of March 31, 1998.






























   The accompanying notes are an integral part of these financial statements.
                                       F-5


<PAGE>



Note 1 - Account Policies

Basis of Presentation
The condensed financial  statements of Surgical Safety Products,  Inc. (Company)
have been prepared  without audit,  pursuant to the rules and regulations of the
Securities and Exchange Commission. Certain information and footnote disclosures
normally included in financial  statements prepared in accordance with generally
accepted  accounting  principles have been condensed or omitted pursuant to such
rules and regulations. These consolidated financial statements should be read in
conjunction  with the  financial  statement  and notes  thereto  included in the
Company's Annual Report on Form 10-KSB for the year ended December 31, 1998.

The results of  operations  for the three month  period ended March 31, 1999 are
not necessarily indicative of the results to be expected for any other period or
for the full year.

In the opinion of Company's  management  the  accompanying  unaudited  financial
statement  contains  all  adjustments,  consisting  of only  normally  recurring
adjustment,  necessary to present  fairly the  financial  positions of March 31,
1999,  the results of operations and cash flows for the three months ended March
31, 1999 and March 31, 1998.

Net Loss Per Share
Net loss per share has been computed in accordance  with  Statement of Financial
Accounting  Standards (FASB) no. 128, "Earnings Per Share," by dividing net loss
by the weighted average number of shares outstanding  during the period.  Common
stock  equivalents  have not been include in the computation of weighted average
number of shares outstanding since the effect would have been anti-dilutive.

Reclassifications
Certain reclassification have been made in the prior year's financial statements
to conform to the current period presentations.

Note 2 - Stock Compensation Expense
During fiscal year 1998, the Company issued stock options with an exercise price
that was below  market to certain of its  employees.  Accordingly,  the  Company
recorded  $91,113 of  compensation  expense related to the issuance for the year
ended December 31, 1998.

In the first  quarter of 1999,  the Company  canceled  these  stock  options and
issued  options with an exercise  price above that of market.  Accordingly,  the
Company  decreased its payroll expenses by $91,113 for the cancellation of these
options for the quarter ended March 31, 1999.



                                       F-6



<PAGE>



Item 2. Management's Discussion and Analysis or Results of Operations.

General

     In March 1999, the Company installed additional units under the US Surgical
agreement at the  California  Pacific  Medical  Center and the Kaiser  Permeante
Medical Center, both in San Francisco, California.

     In April, 1999, the Company shipped and did the preliminary installation at
three more US Surgical sites, a second California  Pacific Medical Center in San
Francisco, the California Pacific Medical Center in Los Angeles,  California and
the University of Washington in Seattle,  Washington.  All of these installation
are awaiting final connection and networking.

     In April 1999, the Company again  attended the AORN  convention at which it
experienced more acceptance from potential  content  providers and users because
of the commencement of the arrangement with US Surgical.

     The Company expects to complete the last three (3) US Surgical cites in May
and June 1999.

     In April 1999 the  Company  commenced  a  self-directed  private  placement
offering of the Company's  restricted Common Stock and warrants for an aggregate
of $500,000 in proceeds.  This offering is being  conducted  pursuant to Section
4(2) of the  Securities  Act of  1933,  as  amended  (the  "Act")  and  Rule 506
promulgated  under Regulation D of the Act to not more than thirty-five (35) non
accredited   investors;   Section  517.061(11)  of  the  Florida  Code,  Section
292.410(h)  of  the  Kentucky  Code  and  Section  201.[70  P.S.  1/201]  of the
Pennsylvania  Code..  No  memorandum  is  being  used in  connection  with  this
offering.

     The basis for reliance upon the Section 4(2)  exemption in connection  with
this  offering is (i) the sale of the shares of Common Stock and  warrants  does
not constitute a public offering and (ii) investors are or will be sophisticated
investors who have access to the information on the Company necessary to make an
informed investment decision by virtue of the Company's  Registration  Statement
on Form 10-SB,  as amended,  filed with the Securities  and Exchange  Commission
(the "SEC") and the  Company's  Form 10-KSB  filed with the SEC.  The Company is
required to file a Form D within fifteen (15) days of the first sale.  Thus far,
the Company has received  gross proceeds of $75,000 under this offering from two
(2) investors for a total of 150,000 shares of the Company's  restricted  Common
Stock and the  issuance of warrants to purchase a total of 75,000  shares of the
Company's Common Stock at an exercise price of $1.00 within five (5) years.

     The basis for  reliance  upon  Section  517.061(11)  of the Florida Code in
connection  with this offering is (i) sales of the shares of  restricted  Common
Stock and  warrants has been or will be made to not more than  thirty-five  (35)
persons;  (ii)  neither  the offer nor the sale of any of the shares has been or
will be accomplished by the publication of any  advertisement;  (iii) all of the
purchasers either have or had a pre-existing  personal or business  relationship
with one or more of the  executive  officers and directors of the Company or, by
reason of their business or financial experience, could be reasonably assumed to
have the capacity to protect their own interest in connection with the


<PAGE>



transaction;  (iv) each  purchaser has or will  represent that he was purchasing
for his own  account and not with a view to or for sale in  connection  with any
distribution  of shares;  and (v) prior to sale, each purchaser had or will have
reasonable  access to or was  furnished  all  material  books and records of the
Company,  all material contracts and documents relating to the Company,  and had
an opportunity to question the executive officers of the Company.

     The basis for reliance  upon  Section  292.410(h)  of the Kentucky  Code in
connection  with this  offering  is (i) neither the offer nor the sale of any of
the shares has been or will be accomplished by any form of general solicitation;
(ii) the Company has received or will receive a written  representation from the
purchaser  that he is acquiring the  securities  for his own  investment  and is
aware  of any and all  restrictions  imposed  on  transferability  and  that the
certificates and warrants do and shall bear a restrictive legend; (iii) sales of
the shares of  restricted  Common Stock and warrants has been or will be made to
not more  than  fifteen  (15)  persons  in  Kentucky  all of whom will be or are
accredited investors;  and (iv) there are no commissions,  finders fees or other
remunerations being paid in connection with the sales.

     The  basis  for  reliance  upon  Section   201.[70  P.S.   1.201]  is  that
Pennsylvania  does not  require  registration  of  federally  exempted  Rule 506
securities.

     In April, 1999, the Company executed a Consulting and Assistance  Agreement
with Koritz Group LLC, a Connecticut limited liability company ("Koritz"). Under
the terms of this  agreement,  Koritz has been  engaged to  identify  sources of
capital or  potential  business  relationships  and to assist the Company in (i)
raising equity or debt financing in the amount of $15,000,000 (ii) arranging for
trade financing for  production,  sale,  lease,  rental or other disposal of the
Company's  products;  and (iii) arranging for the sale, merger, or consolidation
of the  Company  or  for  joint  ventures  or  strategic  alliances  with  other
appropriate  business.  This agreement is non-exclusive.  In the event Koritz is
successful,  2.5% for any trade  financing and 10% of the value of each business
arrangement.  In the event Investment Financing is secured, the Company will pay
compensation  equal to 10% for any investment  financing to the person or entity
placing such investment;  provided such person or entity is qualified to receive
such compensation in the state of residence of the investor. The Company is free
to reject any offered financing or arrangements;  however, in the event that the
Company  enters any  arrangement  within 180 days of its written  rejection,  on
terms less favorable to the Company, Koritz will receive a flat fee of $100,000.
In  addition  to  the  cash  compensation,  in the  event  the  Company  secures
investment financing, then the qualified,  placing person or entity will receive
warrants to purchase the Company's Common Stock  exercisable for 36 months after
the closing at the same price as the investment  financing source receives,  the
number of which warrants is equal to the amount of the financing  divided by the
exercise price.  Such warrants have  anti-dilution  and piggy-back  registration
rights.  Should the Company  "shop" any offer of  financing  presented  to it to
other potential sources and accept such other financing,  the Koritz is entitled
to a success  fee.  Koritz will be  reimbursed  pre-approved  disbursements  and
expenses. The agreement provides for confidentiality and cross-indemnification .
The agreement may be canceled by either party with five (5) days written notice.
Any disputes  under the agreement  are required to be submitted to  arbitration,
which costs payable by the losing party.




<PAGE>



Discussion and Analysis

     The  Company  was  founded  in 1992  to  combat  the  potential  spread  of
bloodborne pathogenic infections such as HIV and hepatitis. It has broadened its
mission to  research,  develop,  manufacturing,  marketing  and selling  medical
products and services to the healthcare community.

     The  Company  was in  the  development  stage  until  1993  when  it  began
commercial  shipments of  SutureMate(R),  its first  product.  From inception in
June,  1992  through  December  31,  1998,  the  Company  generated  revenues of
approximately  $1,100,000  from a limited number of customers.  Since  inception
through  December  31,  1998,  the Company has  generated  cumulative  losses of
approximately  $1,690,000.  Although the Company has  experienced  a significant
percentage  growth in revenues from fiscal 1992 to fiscal 1998, the Company does
not believe  prior  growth rates are  indicative  of future  operating  results,
especially  in  light  of  the  contract  with  US  Surgical  to  assist  in the
introduction  of OASiS.  Due to the  Company's  operating  history  and  limited
resources,  among other factors, there can be no assurance that profitability or
significant  revenues on a quarterly  or annual  basis will occur in the future.
Moreover,  the Company expects to continue to incur operating  losses through at
least the first half of 2000, and there can be no assurance that losses will not
continue after such date.

     With the  implementation of its agreement with US Surgical and in the event
of the  reactivation  of its  various  distribution  agreements  and/or with the
establishment  of one or  more  strategic  alliances,  the  Company  expects  to
experience a period of growth,  which requires it to significantly  increase the
scale of its  operations.  This  increase  will include the hiring of additional
personnel in the areas of (i) customer service to provide  technical support for
the hospitals at which  installations  are located and (ii)  technical  staff to
make  changes  requested  by the  installation  hospitals.  This will  result in
significantly  higher operating expenses.  The increase in operating expenses is
expected  to be  partially  funded by an  increase  in  revenues.  However,  the
Company's  net  loss  may  continue  to  increase.  Expansion  of the  Company's
operations may cause a significant strain on the Company's management, financial
and other  resources.  The  Company's  ability to manage recent and any possible
future growth,  should it occur, will depend upon a significant expansion of its
research and development,  accounting and other internal  management systems and
the  implementation  and  subsequent   improvement  of  a  variety  of  systems,
procedures and controls.  There can be no assurance that significant problems in
these areas will not occur.  Any failure to expand these areas and implement and
improve such systems,  procedures and controls in an efficient  manner at a pace
consistent with the Company's  business could have a material  adverse effect on
the Company's  business,  financial  condition and results of  operations.  As a
result of such expected expansion and the anticipated  increase in its operating
expenses,  as well as the difficulty in forecasting  revenue levels, the Company
expects to continue to  experience  significant  fluctuations  in its  revenues,
costs and gross margins, and therefore its results of operations.

     The Company's  plan of operations for the next twelve months is to focus on
building  revenue  from the  installation  of the  OASiS  system in the ten (10)
hospitals  designated by US Surgical and to install  additional OASiS systems in
hospitals  not under the US  Surgical  agreement  but with whom the  Company has
begun  negotiations  and in some cases reached a commitment.  Additionally,  the
Company intends to install the inservice modules from US Surgical and other


<PAGE>



medical product  manufacturers  at both the US Surgical and the other hospitals.
The Company  also is seeking  aggressively  strategic  alliances  with  targeted
industry   partners  such  as   manufacturers   of  devices,   manufacturers  of
pharmaceuticals,  professional  organizations  such as nursing  associations and
hospital group purchasing organizations and integrated health networks.

     The  Company  estimates  that  if  it is  successful  in  consummating  new
strategic  alliances,  the  agreements  will provide for infusion of  sufficient
capital to fund  ongoing  operations  for the  balance of the year.  The Company
estimates  revenues  from an expanded base of content  providers and  individual
installations may grow to the level where they can support ongoing operations.

     The Company  estimates  that  revenues  will be  sufficient to fund ongoing
operations at the current level when the number of OASiS  installations  reaches
30 to 35 and the total number of inservice  modules  reaches 60-70.  The Company
has purchased 20 OASiS units from Kiosk  Information  Systems,  Inc., 3 of which
were installed under the US Surgical agreement, 3 of which were installed at St.
Francis Hospital, and the balance of which are dedicated to its commitment to US
Surgical for  hospitals  it has ready for  installation  and to other  hospitals
which are committed to proceed,  which  installations are scheduled on or before
June 30, 1999. Based upon potential additional commitments, the Company believes
that if it were to order 20 more  units,  that all such units would be placed by
the end of the third quarter 1999. The Company already has 30 inservice  modules
under the US Surgical agreement and is in discussion with various  manufacturers
interested  in using  OASiS to  inservice  more than 50 of their  products.  The
Company believes that each of the initial  installations  should have a position
as to long term  acceptance  within  three (3) to six (6)  months  and that this
initial time is the test period to determine the potential for market acceptance
at that hospital. In the case of US Surgical hospitals,  this period will be for
nine (9)  months  by  contract.  At the end of such  test  period,  the  Company
believes it will be in a position  to execute  three (3) year leases and finance
such leases through the Rockford leveraged leasing arrangement.

     In the short term, to fund  operations  through the third quarter 1999, the
Company will be required to seek additional  funds from its  shareholders,  seek
funds from a limited  number of accredited  investors in a private  placement of
its restricted  securities,  seek additional third party financing or seek third
party  debt  or  equity  financing  other  than  those  planned  by the  current
anticipated private placement. In the event no such funding is available or only
partial  funding  is  available,  the  Company  will be  required  to scale back
operations  and to  reduce  its  breakeven  point  by such  measures  as  salary
reductions,  staffing  cuts,  or the  licensing or sale of some of the Company's
assets or product lines to third parties. Provided such funding or scale back is
successful,  the Company believes that it can meet its capital needs through the
testing period and until such time as the Company has sufficient additional long
term  capital to expand.  There can be no  assurance  that the  Company  will be
successful in these efforts.

     Once the testing period is over, the Company will require between $2 and $5
million  in  additional  capital  in the  form  of debt or  equity  to fund  the
continued  expansion of the OASiS system and its  development  to meet increased
demand and to implement its plans for increased  marketing of its medical device
products.  The Company has met with several  venture  capital firms,  investment
bankers,  factoring companies and traditional lending sources, each of whom have
expressed  early  interest and many of whom are awaiting the  conclusion  of the
testing period. No definite offer has been accepted by the Company.  There can


<PAGE>



be no assurance  that such long term  financing will be available to the Company
or that it will be on terms which the Company may seek.

Results of Operations for the Three Months Ended March 31, 1999 and 1998

Overview

     From its inception, the Company has incurred losses from operations.  As of
March 31, 1999,  the Company had cumulative  net losses  totaling  approximately
$1,799,000. Through fiscal 1997, the Company focused primarily on the design and
development of its propriety products, as well as providing consulting services.
During fiscal 1998,  management shifted its focus to aggressively  marketing its
proprietary products.

Financial Position

     Working  capital as of March 31, 1999 decreased to a deficit of $241,769 as
compared to working  capital of $53,056 at December 31, 1998.  This  decrease is
primarily  due to an increase in  accounts  payable of $45,568,  advances on the
line of credit of  $100,000  and loans  from the major  stockholder  of  $70,000
during the three months ended March 31, 1999.

Revenues

     For the three ended March 31, 1999 and 1998, the Company had total revenues
of $39,577 and $15,980, respectively.  Revenues for the three months ended March
31, 1998 are comprised  primarily of consulting fees. For the three months ended
March 31,  1999,  revenues are  comprised of fees  received for unit rentals and
production fees for inservice modules.

Selling, General, and Administrative Expenses

     For the three months ended March 31, 1999,  operating expenses increased by
$75,710 or 120% from $63,274 for the three  months  ended March 31,  1998.  This
increase is  primarily  related to selling and  staffing  costs to initiate  the
OASiS  installations.  Payroll  and  related  expenses  decreased  to a negative
$10,000 due to the  cancellation of stock options issued during fiscal 1998. Had
these options not been canceled,  payroll expenses would have increased  $70,000
to $87,860 for the three  months  ended March 31, 1999 from  $17,860  during the
three months ended March 31, 1998.  In accordance  with the Company's  marketing
plan  for  fiscal  1999,  expenses  related  to  promotion,   trade  shows,  and
conventions  increased  $33,540 to $45,815 for the three  months ended March 31,
1999 as compared to $12,275 for the three months ended March 31, 1998.

      In the past,  the  Company has  focused on the design and  development  of
proprietary  products.  For fiscal 1999,  the Company has launched an aggressive
marketing  plan that is designed to increase  worldwide  sales of its  products.
Surgical feels that the increased  operating  expenses incurred during the three
months  ended March 31,  1999 will  position  the Company to generate  increased
product sales in the second half of the fiscal year.



<PAGE>



Liquidity and Capital Resources

     The Company's  operations are being funded  primarily from the cash flow of
$170,000  generated  from  shareholder  loans and advances on the line of credit
during the three  months  ended  March 31,  1999.  This  allowed  the Company to
purchase capital assets, enhance its OASiS software and fund current operations.
At March 31, 1999, the Company is in a $0 cash position. Subsequent to March 31,
1999, receipts from the Company's self directed private placement have been used
to fund  operations and the Company has several other  investors which have been
committed but not reduced to writing as of this date.

     The Company has a line of credit in the amount of $100,000 which expires in
May 2017 and is guaranteed by Dr. Swor and his wife. The line of credit also has
been used to fund  operations  on a  short-term  basis and $100,000 is currently
outstanding.

     Net cash used for  investing  for the three months ended March 31, 1999 was
approximately  $67,000,  representing primarily costs related to the new version
of OASiS which have been capitalized.

     Revenues  of  $39,577  for the  quarter  ended  March  31,  1999  have been
generated  primarily  from the  leasing  of OASiS  units  to  various  hospitals
pursuant  to the  Agreement  with US  Surgical.  Leasing and  installation  fees
related to the  Agreement  accounted for 99% of the revenue  generated.  For the
quarter  ended  March 31,  1998,  $15,355 or 96% of  revenues  of  $15,980  were
generated from consulting services provided to US Surgical.

     It is the  Company's  intention  to  pursue  additional  debt and or equity
financing in the range of $2,000,000 to $5,000,000  during the remaining part of
fiscal 1999, however,  there can be no assurance that they will be successful in
their efforts.  Surgical  believes that cash flows generated from operations and
borrowing capacity, combined with proceeds from future debt or equity financing,
will provide  adequate  flexibility  for funding the Company's  working  capital
obligations.

Impact of the Year 2000 Issue

     The Year 2000  Issues is the result of  potential  problems  with  computer
systems or any equipment  with computer  chips that use dates where the date has
been stored as just a two digits  (e.g.  98 for 1998).  On January 1, 2000,  any
clock or date recording  mechanism  including date sensitive software which uses
only two digits to represent  the year,  may  recognize the date using 00 as the
year 1900 rather than the year 2000.  This could  result in a system  failure or
miscalculations causing disruption of operations,  including among other things,
a temporary  inability  to process  transactions,  send  invoices,  or engage in
similar activities.

     The  Company  determined  that the Year  2000  impact  is not  material  to
Surgical  and that it will not  impact its  business,  operations  or  financial
condition  since all of the internal  software  utilized by the Company is being
upgraded to support Year 2000 versions.  Further,  the Year 2000 will not impact
upon the  operation  of the OASiS system since the software for this system does
not rely on legacy applications or subsystems.  OASiS is designed to handle


<PAGE>



dates in the form of a two  digit  month  and day and a four  digit  year,  thus
avoiding the Year 2000 problem

     The  Company  believes  that  it has  disclosed  all  required  information
relative to Year 2000 issues relating to its business and  operations.  However,
there can be no  assurance  that the  systems  of other  companies  on which the
Company's systems rely also will be timely converted or that any such failure to
convert by another  company  would not have an adverse  affect on the  Company's
systems.

Forward-Looking Statements

     This Form 10-QSB includes  "forward-looking  statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities  Exchange  Act of  1934,  as  amended.  All  statements,  other  than
statements of historical  facts,  included or  incorporated by reference in this
Form 10-QSB which address  activities,  events or developments which the Company
expects or anticipates will or may occur in the future, including such things as
future capital  expenditures  (including the amount and nature thereof),  demand
for the Company's  products and services,  expansion and growth of the Company's
business and operations, and other such matters are forward-looking  statements.
These  statements  are based on certain  assumptions  and  analyses  made by the
Company in light of its  experience  and its  perception of  historical  trends,
current conditions and expected future  developments as well as other factors it
believes are appropriate in the circumstances.  However,  whether actual results
or developments will conform with the Company's  expectations and predictions is
subject  to a number of risks and  uncertainties,  general  economic  market and
business  conditions;  the business  opportunities (or lack thereof) that may be
presented  to and pursued by the  Company;  changes in laws or  regulation;  and
other   factors,   most  of  which  are  beyond  the  control  of  the  Company.
Consequently, all of the forward-looking statements made in this Form 10-QSB are
qualified by these cautionary  statements and there can be no assurance that the
actual results or  developments  anticipated by the Company will be realized or,
even if substantially  realized, that they will have the expected consequence to
or effects on the Company or its business or operations.  The Company assumes no
obligations to update any such forward-looking statements.

                                     PART II

Item 1. Legal Proceedings.

     The  Company  knows  of no legal  proceedings  to which it is a party or to
which any of its  property  is the  subject  which are  pending,  threatened  or
contemplated or any unsatisfied judgments against the Company.

Item 2.     Changes in Securities and Use of Proceeds

      None




<PAGE>

Item 3.     Defaults in Senior Securities

      None

Item 4. Submission of Matters to a Vote of Security Holders.

     No matter was submitted  during the quarter ending March 31, 1999,  covered
by this report to a vote of the Company's shareholders, through the solicitation
of proxies or otherwise.

Item 5.     Other Information

      None

Item 6.     Exhibits and Reports on Form 8-K

     (a) The exhibits  required to be filed  herewith by Item 601 of  Regulation
S-B, as described in the following index of exhibits, are incorporated herein by
reference, as follows:

Exhibit No.             Description
-------------------------------------------------------------------------------

3.(i).1     Articles of  Incorporation  of Surgical  Safety  Products,  Inc., a
            Florida corporation filed May 15, 1992

3.(i).2     Articles of Amendment filed December 9, 1992

3.(i).3     Articles of Amendment filed July 19, 1994

3.(i).4     Articles of Amendment filed October 11, 1994

3.(i).5     Articles of Incorporation of Sheffeld Acres, Inc., a New York
            Corporation filed May 7, 1993

3.(i).6     Articles of Merger filed in the State of Florida October 12, 1994

3.(i).7     Certificate of Merger filed in the State of New York February 8,
            1995

3.(i).8     Certificate to Do Business in the State of Florida filed April 11,
            1995

3.(i).9     Certificate of Amendment filed May 1, 1998

3.(ii).1    Bylaws of Sheffeld Acres, Inc., now known as Surgical Safety
            Products, Inc.

3.(ii).2    Amended Bylaws of Surgical Safety Products, Inc.

10.1        Acquisition of Endex Systems, Inc. d/b/a/ InterActive PIE dated
             December 8, 1997



<PAGE>



10.2        Prepaid Capital Lease Agreement with Community Health Corporation
            relative to Sarasota Medical Hospital OASiS Installation dated
            January 30, 1998

10.3        Letter of Intent with United States Surgical Corporation dated
            February 12, 1998

10.4        Form of Rockford Industries, Inc. Rental Agreement and Equipment
            Schedule to Master Lease Agreement

10.5        Ad-Vantagenet Letter of Intent dated June 19, 1998

10.6        Distribution Agreement with Morrison International Inc. dated
            September 30, 1996

10.7        Distribution Agreement with Hospital News dated August 1, 1997

10.8        Clinical Products Testing Agreement with Sarasota Memorial Hospital
            dated January 30, 1998

10.9        Real Estate Lease for Executive Offices effective June 1, 1998

10.10       Employment Agreement with Donald K. Lawrence dated April 1, 1997

10.11       Employment Agreement with G. Michael Swor dated June 15, 1998

10.12       Employment Agreement with Frank M. Clark dated June 15, 1998

10.13       Agreement for Consulting Services with Stockstowatch.com Inc. dated
            March 30, 1988

10.14       Form of Employee Option Agreement dated July 1994

10.15       Form of Employee Option Agreement dated 1998

10.16       Form of Consultants Option Agreement dated July 1994

10.17       Form of Consultants Option Agreement dated 1998

10.18       Confidential Private Offering Memorandum dated May 30, 1995

10.19       Supplement to Private Offering Memorandum dated October 30, 1995

10.20       Stock Option Agreement with Bay Breeze Enterprises LLC dated
            April 9, 1998

10.21       Revolving Loan Agreement, Revolving Note, Security Agreement with
            SouthTrust Bank dated May 2, 1997



<PAGE>



10.22       Agreement between the Company and T. T. Communications, Inc. dated
            October 15, 1998

10.23       Agreement  between the Company and U.S.  Surgical  Corporation dated
            October 28, 1998.

10.24       Collaborative  Agreement between the Company and Dr. William B. Saye
            dated November 16, 1998.

10.25       Kiosk Information System, Inc. Purchase Order dated November 3, 1998

10.26       Surgical Safety Products 1999 Stock Option Plan adopted January 1999

10.27       Form of the Employee Option Agreement under the Surgical Safety
            Products 1999 Stock Option Plan dated January 1999

10.28       Form of the Director, Consultant and Advisor Option Agreement under
            the Surgical Safety Products 1999 Stock Option Plan dated
            January 1999

10.29       Verio, Inc. Access Service Agreement dated February 16, 1999.

10.30       * Form of Investor Subscription Documents and Agreements relative to
            the April 1999 Self Directed Private  Placement  Offering under Rule
            506 of Regulation D.

10.31       * Form  of the  Warrant  issued  pursuant  to the  April  1999  Self
            Directed Private Placement Offering under Rule 506 of Regulation D.

10.32       * Consulting Agreement dated April 1999 with Koritz Group, LLC.

23.2        Publisher's Consent and Article - Michael W. Bebbington, MD, MHSc
            and Mark J. Treissman, MD.  The Use of a Surgical Assist Device to
            Reduce Glove Perforations in Postdelivery Vaginal Repair: A
            Randomized Controlled Trial.  American Journal of Obstetrics and
            Gynecology, Vol. 175, No. 1, Part I, October 1996

23.3        Author's Consent and Abstract - Donna J. Haiduven, BSN, MSN, CIC and
            Maria D. Allo,  MD.  Evaluation  of a One-Handed  Surgical  Suturing
            Device to Decrease  Intraoperative  Needlestick  Injuries  and Glove
            Perforations:   Phases  I  &  II,   Conference   on   Prevention  of
            Transmission  of  Bloodborne  Pathogens  in Surgery  and  Obstetrics
            Sponsored  by the  American  College of Surgeons  and the Center for
            Disease Control and Prevention, February 13-15, 1994, Atlanta, GA.

23.4        Publisher's Consents and Article - Mark S. Davis, MD.  Sharps
            Management in Surgery.  Infection Control & Sterilization
            Technology, Vol. 1, No. 4, April 1995.

27.1        * Financial Data Street


<PAGE>



----------------

(* Filed  herewith,  all other  exhibits  previously  filed as  exhibits  to the
Company's Form 10-SB and Form 10-SB Amendment No. 1)

     (b) No Reports on Form 8-K were filed  during the  quarter  ended March 31,
1999.


                                   SIGNATURES

      In accordance with Section 12 of the Securities  Exchange Act of 1934, the
registrant caused this Registration  Statement to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                                 Surgical Safety Products, Inc.
                                                       (Registrant)


Date: May 24, 1999                         By:/s/ Frank M. Clark
                                ------------------------------------------------
                                         Frank M. Clark, President and CEO


                               By:/s/ Donald K. Lawrence
                                  ------------------------
                                   Donald K. Lawrence
                                   Vice President and Secretary


                               By:/s/ G. Michael Swor
                                  ---------------------
                                   G. Michael Swor
                                   Treasurer


                               By:/s/ David Collins
                                  ------------------
                                   David Collins
                                   Acting Chief Financial Officer


[sign page SSP 10QSB 3.31.99]